Medline Statistics
Total Valuation
Medline has a market cap or net worth of $43.60 billion. The enterprise value is $53.54 billion.
| Market Cap | 43.60B |
| Enterprise Value | 53.54B |
Important Dates
The last earnings date was Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Medline has 1.31 billion shares outstanding. The number of shares has decreased by -94.99% in one year.
| Current Share Class | 877.35M |
| Shares Outstanding | 1.31B |
| Shares Change (YoY) | -94.99% |
| Shares Change (QoQ) | +4.37% |
| Owned by Insiders (%) | 1.11% |
| Owned by Institutions (%) | 60.62% |
| Float | 341.00M |
Valuation Ratios
The trailing PE ratio is 41.67 and the forward PE ratio is 22.49. Medline's PEG ratio is 2.75.
| PE Ratio | 41.67 |
| Forward PE | 22.49 |
| PS Ratio | 1.49 |
| Forward PS | 1.38 |
| PB Ratio | 2.57 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 28.84 |
| P/OCF Ratio | 22.38 |
| PEG Ratio | 2.75 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.13, with an EV/FCF ratio of 35.27.
| EV / Earnings | 77.78 |
| EV / Sales | 1.82 |
| EV / EBITDA | 19.13 |
| EV / EBIT | 29.86 |
| EV / FCF | 35.27 |
Financial Position
The company has a current ratio of 4.33, with a Debt / Equity ratio of 0.66.
| Current Ratio | 4.33 |
| Quick Ratio | 2.45 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 4.23 |
| Debt / FCF | 8.18 |
| Interest Coverage | 2.34 |
Financial Efficiency
Return on equity (ROE) is 4.94% and return on invested capital (ROIC) is 5.08%.
| Return on Equity (ROE) | 4.94% |
| Return on Assets (ROA) | 3.01% |
| Return on Invested Capital (ROIC) | 5.08% |
| Return on Capital Employed (ROCE) | 4.98% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $665,311 |
| Profits Per Employee | $15,578 |
| Employee Count | 45,000 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 4.74 |
Taxes
In the past 12 months, Medline has paid $197.00 million in taxes.
| Income Tax | 197.00M |
| Effective Tax Rate | 18.29% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 38.05 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 37.50 |
| Average Volume (20 Days) | 6,990,759 |
Short Selling Information
The latest short interest is 34.56 million, so 2.63% of the outstanding shares have been sold short.
| Short Interest | 34.56M |
| Short Previous Month | 29.45M |
| Short % of Shares Out | 2.63% |
| Short % of Float | 10.14% |
| Short Ratio (days to cover) | 5.45 |
Income Statement
In the last 12 months, Medline had revenue of $29.94 billion and earned $701.00 million in profits. Earnings per share was $0.80.
| Revenue | 29.94B |
| Gross Profit | 7.85B |
| Operating Income | 1.83B |
| Pretax Income | 1.08B |
| Net Income | 701.00M |
| EBITDA | 2.85B |
| EBIT | 1.83B |
| Earnings Per Share (EPS) | $0.80 |
Balance Sheet
The company has $2.70 billion in cash and $12.64 billion in debt, with a net cash position of -$9.94 billion or -$7.56 per share.
| Cash & Cash Equivalents | 2.70B |
| Total Debt | 12.64B |
| Net Cash | -9.94B |
| Net Cash Per Share | -$7.56 |
| Equity (Book Value) | 19.08B |
| Book Value Per Share | 13.19 |
| Working Capital | 9.03B |
Cash Flow
In the last 12 months, operating cash flow was $1.99 billion and capital expenditures -$446.00 million, giving a free cash flow of $1.55 billion.
| Operating Cash Flow | 1.99B |
| Capital Expenditures | -446.00M |
| Depreciation & Amortization | 1.02B |
| Net Borrowing | -4.11B |
| Free Cash Flow | 1.55B |
| FCF Per Share | $1.18 |
Margins
Gross margin is 26.20%, with operating and profit margins of 6.10% and 2.31%.
| Gross Margin | 26.20% |
| Operating Margin | 6.10% |
| Pretax Margin | 3.60% |
| Profit Margin | 2.31% |
| EBITDA Margin | 9.52% |
| EBIT Margin | 6.10% |
| FCF Margin | 5.16% |
Dividends & Yields
Medline does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 94.99% |
| Shareholder Yield | 94.99% |
| Earnings Yield | 1.57% |
| FCF Yield | 3.47% |
Analyst Forecast
The average price target for Medline is $44.62, which is 34.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $44.62 |
| Price Target Difference | 34.56% |
| Analyst Consensus | Buy |
| Analyst Count | 27 |
| Revenue Growth Forecast (3Y) | 8.47% |
| EPS Growth Forecast (3Y) | 0.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medline has an Altman Z-Score of 2.23 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.23 |
| Piotroski F-Score | 6 |